SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors reduce renal glucose uptake threshold and have been utilized in patients with T2D to lower plasma glucose levels, with limited risk of hypoglycemia and to prevent cardiovascular complications (17).